Ibrutinib was a breakthrough when it was first approved to treat R/R MCL in 2013, and a year later for patients with at least 1 prior treatment for chronic lymphocytic leukemia. However, its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results